尊龙凯时

关于尊龙凯时
研发效劳
效劳平台
客户中心
新闻资讯
投资者关系
人力资源
EN
×
EN

  • 营业咨询

    中国：

    Email: marketing@medicilon.com.cn

    营业咨询专线：400-780-8018

    （仅限效劳咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    外洋：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jun 28,2023
TAK-243是一种有用的泛素激活酶小分子抑制剂，具有体内抗肿瘤功效，通过尊龙凯时使用HCC70模子举行
TAK-243 is a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade. TAK-243 has UAE-specific antitumor efficacy in vivo. Medicilon performed the experiment using the HCC70 (triple-negative breast cancer) model.
审查更多
TAK-243是一种有用的泛素激活酶小分子抑制剂，具有体内抗肿瘤功效，通过尊龙凯时使用HCC70模子举行
Jun 28,2023
法尼基转移酶抑制剂LNK-754单次口服后即可快速穿过血脑屏障，本研究中PK剖析通过尊龙凯时举行
Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.
审查更多
法尼基转移酶抑制剂LNK-754单次口服后即可快速穿过血脑屏障，本研究中PK剖析通过尊龙凯时举行
Jun 28,2023
WYC-209可抑制恶性小鼠玄色素瘤肿瘤再生细胞增殖，本研究中SPR通过尊龙凯时使用Biacore 8K举行
The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.
审查更多
WYC-209可抑制恶性小鼠玄色素瘤肿瘤再生细胞增殖，本研究中SPR通过尊龙凯时使用Biacore 8K举行
Jun 28,2023
ARD-2128是一种PROTAC AR降解剂，具有精彩的血浆和微粒体稳固性，本研究中体外稳固性和PK研究通过尊龙凯时举行
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
审查更多
ARD-2128是一种PROTAC AR降解剂，具有精彩的血浆和微粒体稳固性，本研究中体外稳固性和PK研究通过尊龙凯时举行
Jun 28,2023
设计合成一系列DHODH抑制剂作为潜在的类风湿性枢纽炎治疗药物，本研究中PK实验通过尊龙凯时举行
Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents.
审查更多
设计合成一系列DHODH抑制剂作为潜在的类风湿性枢纽炎治疗药物，本研究中PK实验通过尊龙凯时举行
Jun 28,2023
开发并验证新的LC-MS/MS要领，用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。本研究中OHD(纯度>99%)通过尊龙凯时合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
审查更多
开发并验证新的LC-MS/MS要领，用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。本研究中OHD(纯度>99%)通过尊龙凯时合成
Jun 28,2023
放射疗法用作肺癌的主要治疗要领，本研究中建设抗电离辐射肺癌细胞系的放射治疗通过尊龙凯时举行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
审查更多
放射疗法用作肺癌的主要治疗要领，本研究中建设抗电离辐射肺癌细胞系的放射治疗通过尊龙凯时举行
Jun 28,2023
CAR-T疗法主要针对白血病与恶性淋巴瘤，本研究中构建默然PD-1的shRNA载体质粒，测序后质粒的判断通过尊龙凯时举行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
审查更多
CAR-T疗法主要针对白血病与恶性淋巴瘤，本研究中构建默然PD-1的shRNA载体质粒，测序后质粒的判断通过尊龙凯时举行
Jun 28,2023
索拉非尼的无定形固体疏散体用于开发改良型口服生物使用度高的速释片剂，本研究中PK实验通过尊龙凯时举行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar?. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar? tablets was performed by Medicilon.
审查更多
索拉非尼的无定形固体疏散体用于开发改良型口服生物使用度高的速释片剂，本研究中PK实验通过尊龙凯时举行
Jun 28,2023
TAK-931是一种高特异性CDC7抑制剂，具有抗肿瘤功效，本研究中体内药效实验通过尊龙凯时举行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
审查更多
TAK-931是一种高特异性CDC7抑制剂，具有抗肿瘤功效，本研究中体内药效实验通过尊龙凯时举行
×
搜索验证
点击切换
【网站地图】【sitemap】